New Study Suggests MDMA Can Reduce Symptoms of PTSD, Potential Approval by 2024

New Study Suggests MDMA Can Reduce Symptoms of PTSD, Potential Approval by 2024

A recent study sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) suggests that MDMA, commonly known as Ecstasy or Molly, may be effective in reducing symptoms of post-traumatic stress disorder (PTSD). The study, published in Nature Medicine, involved 104 participants with PTSD who were randomly assigned to receive either MDMA or a placebo pill over the course of three therapy sessions. Both groups were also given talk therapy during the treatment process.

The results of the study showed that the MDMA group experienced significant improvements in their symptoms compared to the placebo group. An assessment measuring PTSD symptoms such as flashbacks, nightmares, and insomnia found that 86% of the participants in the MDMA group showed improvement, compared to 69% in the placebo group. Additionally, 72% of those in the MDMA group no longer met the criteria for a PTSD diagnosis, compared to 48% in the placebo group.

It is worth noting that some side effects were observed in the MDMA group, including nausea, sweating, muscle tightness, and decreased appetite. Despite these side effects, the potential benefits of MDMA-assisted therapy for PTSD are promising.

The approval of psychedelic substances for therapeutic use is gaining attention around the world. In July, Australia became the first country to allow psychiatrists to prescribe certain psychedelic substances, including MDMA and psilocybin (found in psychedelic mushrooms), to patients with depression or PTSD. This decision has opened doors for alternative treatment options in mental health care.

Although MDMA has shown promise in the treatment of PTSD, it is important to note that more research is needed to fully understand its efficacy and potential risks. The American Psychiatric Association has not yet endorsed the use of psychedelics in treatment. However, the U.S. Food and Drug Administration (FDA) has designated psilocybin as a “breakthrough therapy” and has provided grants for research on psychedelic drugs.

Based on the progress made in studies sponsored by MAPS and other research organizations, MDMA-assisted therapy for PTSD is on track to be considered for approval by the FDA in 2024. This could potentially provide a new treatment option for individuals suffering from PTSD and improve their quality of life.

– Nature Medicine
– The Associated Press

All Rights Reserved 2021.
| .